Philipp Mohr,Joyce van Sluis,Adrienne H Brouwers et al.
Philipp Mohr et al.
Purpose: Clinical 89Zr-immunoPET relies on semi-quantitative metrics, such as standardised uptake values (SUV) from static imaging at delayed time points. However, SUV can misinterpret target engagement as it ignores plas...
Corrigendum to "radiation dosimetry of the 18 kDa translocator protein ligand [18F]PBR111 in humans" [nuclear medicine and biology, 144-145 (2025); 109,011] [0.03%]
“[18F]PBR111 标记小分子配体的人体内 18 kDa 转位蛋白放射剂量学研究”一文的勘误页（刊载于核医学与生物学，2025 年，144-145 期；2022 年，109,011）
Benjamin B Tournier,Zahra Mansouri,Yazdan Salimi et al.
Benjamin B Tournier et al.
Theranostic nanoparticles: Investigation of superparamagnetic iron oxide nanoparticles intrinsically labeled with Zirconium-89 and Actinium-225 [0.03%]
本征放射性标记的超顺磁氧化铁纳米颗粒的诊疗应用及研究
George Diehl,Zane G Archibald,Katherine Gingrich et al.
George Diehl et al.
Superparamagnetic iron oxide nanoparticles (SPIONs) are of interest for use as drug delivery vehicles due to their magnetic properties, tunable surface chemistry, and potential for use in magnetic resonance imaging and hyperthermia studies....
[18F]BCPP-BF-PET as an imaging tool for mitochondrial dysfunction in diabetic pancreatopathy and nephrotoxicity [0.03%]
[18F]BCPP-BF正电子发射断层扫描用于糖尿病胰病和肾毒性的线粒体功能障碍成像工具
Yuki Tomonari,Masakatsu Kanazawa,Shingo Nishiyama et al.
Yuki Tomonari et al.
Purpose: [18F]BCPP-BF-PET imaging of mitochondrial complex I was validated as a biomarker of hyperglycaemia- and hyperlipidaemia-induced pancreatic and renal dysfunction in a type 2 diabetes mellitus (T2DM) animal model. ...
Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy [0.03%]
α粒子的放射生物学效应及靶向α粒子治疗的科学依据
Pedro Cruz-Nova,Maydelid Trujillo-Nolasco,Liliana Aranda-Lara et al.
Pedro Cruz-Nova et al.
Targeted alpha therapy (TAT) uses alpha-emitting radionuclides to deliver high-energy radiation directly to a specific biological target. TAT has shown promising results in the treatment of advanced metastatic disease and has demonstrated g...
Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties [0.03%]
三硫醇配体提供高摩尔活性和有前景的体内性质的肿瘤靶向191Pt复合物
Honoka Obata,Atsushi B Tsuji,Yutian Feng et al.
Honoka Obata et al.
Purpose: The Auger electron-emitting radionuclide 191Pt is a promising candidate for radiopharmaceutical therapy. Herein, we explored novel labeling methods for 191Pt using thiol-containing ligands to improve the in vivo ...
A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation [0.03%]
一种针对前列腺癌治疗的新型协同药物组合：细胞外信号调节激酶抑制剂与[177Lu]Lu-rhPSMA-10.1的结合：一项临床前评估的结果
Caroline Foxton,Bart Cornelissen,Edward O&#x;Neill et al.
Caroline Foxton et al.
Purpose: The prostate-specific membrane antigen (PSMA)-targeted radiohybrid ligand [177Lu]Lu-rhPSMA-10.1 is a promising next-generation radiopharmaceutical therapy in prostate cancer. This preclinical evaluation comprised...
Comparative evaluation of radiolabeled bombesin analogs [177Lu]Lu-AMBA and [177Lu]Lu-RM2 for targeting GRPR in glioblastoma model [0.03%]
放射标记的类Bombesin化合物[177Lu]Lu-AMBA和[177Lu]Lu-RM2在靶向胶质母细胞瘤模型中胃泌素释放肽受体的比较研究
Michal Grzmil,Muriel Aline Spahn,Philipp Berger et al.
Michal Grzmil et al.
Introduction: Radiolabeled agonist ligands bind to and activate target receptors, inducing internalization and delivering radionuclides into the inner cancer cells. In contrast, receptor-bound antagonizing radiopeptides i...
Preclinical evaluation of [225Ac]Ac-PSMA-617 and in vivo effect comparison in combination with [177Lu]Lu-PSMA-617 for prostate cancer [0.03%]
前列腺癌的[225Ac]Ac-PSMA-617的临床前评估及其与[177Lu]Lu-PSMA-617联合应用的体内效果比较
E Savio,L Reyes,J Giglio et al.
E Savio et al.
Introduction: The interest in targeted alpha therapy (TAT) has grown in the recent years as it can provide new treatment options for advanced- and late-stage cancer. In this sense, the use of actinium-225 is rising showin...
Exploration of the utilization of irreversible cysteine protease inhibitor in FAP-targeted radiopharmaceuticals design to increase tumor residence time [0.03%]
不可逆半胱氨酸蛋白酶抑制剂在FAP靶向放射性药物设计中增加肿瘤滞留时间的研究探索
Katie Brake,Audifás-Salvador Matus-Meza,Purnima Rawat et al.
Katie Brake et al.
Introduction: Fibroblast activation protein (FAP) is highly upregulated in the stroma of >90 % of epithelial cancers with restricted expression in normal tissues, making it an attractive drug target. Efforts by numerous l...